CEO Daniel O'Connell stated that "in the third quarter, we continued our track record of operational execution on 2 fronts: the steady progression of our Phase II ALTITUDE-AD trial and the generation ...
Management reaffirmed expectations for top line results from ALTITUDE-AD in late 2026, inclusive of key efficacy and safety measures. O'Connell stated, "We expect to make a development decision for up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results